ArticleFrontiers in public health2020
Antibody Profiling of COVID-19 Patients in an Urban Low-Incidence Region in Northern Germany.
Article in Frontiers in public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- COVID-19 antibody responses in individuals with natural immunity and with vaccination-induced immunity: a systematic review and meta-analysis.Systematic reviews · 2024Pooled it
- Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.PLoS medicine · 2020Pooled it
- Pooled it
- Dynamics of immunity over time: decline of anti-SARS-CoV-2 IgG antibodies and T-cell responses after mRNA vaccination in residents and health care workers in nursing homes and homes with assisted living support.GMS infectious diseases · 2023Article
- Sample-to-Answer Immuno-Magnetic Assay Using Thermally Responsive Alkane Partitions.Biosensors · 2022Article
- Vaccination Against SARS-CoV-2 in Lung Transplant Recipients: Immunogenicity, Efficacy and Safety.Frontiers in immunology · 2022Review
- A Probable Covid-19 Case Presented with Acute Upper Limb İschemia.Annals of vascular surgery · 2021Article
- Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel.European journal of epidemiology · 2021Article
- Reconciling estimates of global spread and infection fatality rates of COVID-19: An overview of systematic evaluations.European journal of clinical investigation · 2021Review
- SARS-CoV-2 antibody seroprevalence in NHS healthcare workers in a large double-sited UK hospital.Clinical medicine (London, England) · 2021Article
- Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection.Frontiers in public health · 2021Article
- Infection fatality rate of COVID-19 inferred from seroprevalence data.Bulletin of the World Health Organization · 2021Review
- Estimating the false-negative test probability of SARS-CoV-2 by RT-PCR.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2020Review
- Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England.The Journal of infection · 2020Article
- SARS-CoV-2-IgG response is different in COVID-19 outpatients and asymptomatic contact persons.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2020Article
- Antibody Profiling of COVID-19 Patients in an Urban Low-Incidence Region in Northern Germany.Frontiers in public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A vast majority of COVID-19 cases present with mild or moderate symptoms. The study region is in an urban and well-defined environment in a low-incidence region in Northern Germany. In the present study, we explored the dynamics of the antibody response with respect to onset, level and duration in patients with confirmed SARS-CoV-2 infection. Anti-SARS-CoV-2 IgG and IgA were detected by automated enzyme-linked immunosorbent assay (ELISA) of SARS-CoV-2 infected patients monitored by the Health Protection Authority. This explorative monocentric study shows IgA and IgG antibody profiles from 118 patients with self-reported mild to moderate, or no COVID-19 related symptoms after laboratory-confirmed infection with SARS-CoV-2. We found that 21.7% and 18.1% of patients were seronegative for IgA or IgG, respectively. Clinically, most of the seronegative patients showed no to only moderate symptoms. With regard to antibody profiling 82% of all patients developed sustainable antibodies (IgG) and 78% (IgA) 3 weeks or later after the infection. Our data indicate that antibody-positivity is a useful indicator of a previous SARS-CoV-2 infection. Negative antibodies do not rule out SARS-CoV-2 infection. Future studies are needed to determine the functionality of the antibodies in terms of neutralization capacity leading to personal protection and prevention ability to transmit the virus as well as to protect after vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.